ResultsIQ

ResultsIQ › Latest results › TruAlt Bioenergy Limited

TruAlt Bioenergy Limited Q2 FY27 earnings call summary

NSE: TRUALT · BSE: 544545

Earnings call of 26 Oct 2026, summarised by AI from the filing.

Management expects a 1% or 2% drop in average EBITDA margins this year once tenders are located.

Key takeaways

  1. Margin guidance Management expects a 1% or 2% drop in average EBITDA margins this year once tenders are located.
  2. Raw material risk El Nino expected to cut maize availability about 35% next year, keeping raw material prices elevated.

Original filing on BSE

TruAlt Bioenergy Limited Q2 FY27 results

As filed: Revenue ₹811 cr (+300% year on year), EBITDA ₹101 cr, PAT ₹35.0 cr, EBITDA margin 12.5% (+1,000 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹627 cr (+106% year on year), EBITDA ₹133 cr (+216% year on year), PAT ₹59.3 cr (+300% year on year), EBITDA margin 21.2% (+736 bps). Score 100 of 100, Above trend. EBITDA margin rose 736 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +3.5% in 30 days (Nifty 500: +1.6%).
  • Q4 FY26: Revenue ₹603 cr, EBITDA ₹131 cr, PAT ₹56.7 cr, EBITDA margin 21.7%. Not scored. No result for the same quarter last year. Share price after the results: −0.7% in 28 days (Nifty 500: +2.2%).
  • Q3 FY26: Revenue ₹703 cr, EBITDA ₹129 cr, PAT ₹66.0 cr, EBITDA margin 18.4%. Not scored. No result for the same quarter last year. Share price after the results: −6.8% in 30 days (Nifty 500: −3.2%).
  • Q2 FY26: Revenue ₹104 cr, EBITDA −₹12.0 cr, PAT −₹43.0 cr, EBITDA margin -11.5%. Not scored. No result for the same quarter last year. Share price after the results: −11.7% in 30 days (Nifty 500: +0.2%).
  • Q1 FY26: Revenue ₹294 cr, EBITDA ₹34.0 cr, PAT ₹0.0 cr, EBITDA margin 11.6%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

TruAlt Bioenergy Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.